PYPD Polypid announces exclusive partnership with azurity Pharmaceuticals for the commercialization of D-plex₁₀₀ in the U.S. and Canada Poly
PYPD Polypid announces exclusive partnership with azurity Pharmaceuticals for the commercialization of D-plex₁₀₀ in the U.S. and Canada Polypid - to receive over $320M in payments plus tiered royalties - To receive $15M upfront and $15M on FDA NDA Acceptance
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.